Celebrating Innovation and Legacy: Geistlich Pharma’s 11th Annual Philip J. Boyne Scholarship Award

December 07, 2023

Geistlich Pharma North America, Inc. proudly announces the successful conclusion of the 11th annual Philip J. Boyne Scholarship Award. This prestigious scholarship, born out of the shared enthusiasm for innovation and bone regeneration between Dr. Philip J. Boyne and Dr. Peter Geistlich, continues to make a lasting impact on the field. The scholarship, established to honor the memory and collaborative spirit of these two pioneers, recognizes and supports residents who embody their commitment to advancing oral and maxillofacial surgery.

Honoring a Legacy:

The friendship between Dr. Philip J. Boyne and Dr. Peter Geistlich laid the foundation for groundbreaking developments in the field, culminating in the creation of Geistlich Bio-Oss®. To pay tribute to their enduring legacy, Geistlich Pharma North America, Inc. established the Philip J. Boyne Scholarship, an initiative that serves as a beacon for aspiring professionals who share the same spirit of innovation.

A Decade of Support and Empowerment:

Since its inception in 2011, the Philip J. Boyne Scholarship has empowered hundreds of residents from Oral and Maxillofacial Surgery (OMS) Programs across the country. These aspiring professionals have been given the invaluable opportunity to participate in the AAOMS Dental Implant Conference held annually in Chicago. This exposure to cutting-edge research, techniques, and networking has played a role in shaping the future of oral and maxillofacial surgery.

Commitment to Excellence:

This year, the commitment to excellence and the advancement of the field reached new heights, with scholarships awarded to 40 residents. Geistlich Pharma North America, Inc. continues to demonstrate its dedication to fostering the next generation of leaders and innovators.

Recognition and Celebration:

The culmination of this year’s scholarship program was celebrated at the annual cocktail reception on November 30, 2023, at the Sheraton Grand Hotel, Chicago, coinciding with the AAOMS Dental Implant Conference. This event provided a platform to recognize the outstanding achievements of the scholarship recipients, creating an atmosphere of camaraderie and collaboration among professionals in the field.

Geistlich Pharma North America, Inc. remains at the forefront of advancing oral and maxillofacial surgery through its commitment to innovation and education. The Philip J. Boyne Scholarship stands as a testament to the company’s dedication to nurturing the talents and aspirations of the next generation, ensuring a legacy of excellence in the ever-evolving field of oral and maxillofacial surgery.

About Geistlich North America Inc.

With over 170 years of regenerative expertise, Geistlich continues to lead oral regeneration with an expanding portfolio of intentionally designed and clinically proven products.

This begins with our world-class bone substitute Geistlich Bio-Oss® and Geistlich vallomix™, the first allograft/xenograft bone substitute. Resorbable collagen membrane Geistlich Bio-Gide® extends its reach with Geistlich Bio-Gide® Compressed for an alternative handling experience.

Our collagen matrix Geistlich Mucograft® is ideal for soft-tissue regeneration, and our volume-stable collagen matrix breakthrough Geistlich Fibro-Gide® provides an alternative to connective tissue grafts. Finally, our GEM 21S®, a growth-factor-enhanced matrix, is engineered to stimulate wound healing and bone regeneration.

Our dedication to scientific collaboration and commitment to successful treatment outcomes are what makes Geistlich Biomaterials Exactly Like No Other.

Geistlich Pharma North America Inc.
400 Alexander Park Drive, Suite 302
Princeton, NJ 08540 USA

Home Page:


Social Media




  1. iData Research Inc., US Dental Bone Graft Substitutes and other Biomaterials Market, 2022.
  2. iData Inc., European Dental Bone Graft Substitutes and other Biomaterials Market, 2015.